Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic basis of MPN: Beyond JAK2-V617F.

Current hematologic malignancy reports - 1 Dec 2013

Them Nicole C C, Kralovics Robert

Abstract excerpt

The clonal blood disorders polycythemia vera, essential thrombocythemia and primary myelofibrosis belong to the BCR-ABL1-negative myeloproliferative neoplasms and are specified by increased production of terminally differentiated myeloid cells. Clonal evolution, disease initiation and progression are influenced by genetic alterations, often affecting cytokine signaling and gene expression. This review outlines...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Transformation, Neoplastic
Share to Cytokines
Share to Disease Progression

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epigenomics

Share to Janus Kinase 2

Share to Myeloproliferative Disorders

Share to Signal Transduction

Share to Transcription Factors

Source

Identifiers

PMID: 24190690
DOI: 10.1007/s11899-013-0184-z

Genes

ABL1
BCR
JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic basis of MPN: Beyond JAK2-V617F.PMID 24190690Read ↗

Mutations in myeloproliferative neoplasms - their significance and clinical use.Semantic proximity Read ↗

Genetic basis and molecular profiling in myeloproliferative neoplasms.Semantic proximity Read ↗

Molecular and genetic bases of myeloproliferative disorders: questions and perspectives.Semantic proximity Read ↗

Myeloproliferative neoplasms: updates on molecular pathophysiology, diagnosis and treatment strategies.Semantic proximity Read ↗

Genetic and epigenetic alterations of myeloproliferative disorders.Semantic proximity Read ↗

JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.Semantic proximity Read ↗

Advances in Molecular Understanding of Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis: Towards Precision MedicineSemantic proximity Read ↗

Classification, Diagnosis and Management of Myeloproliferative Disorders in the JAK2V617F EraSemantic proximity Read ↗

Molecular Pathogenesis of Myeloproliferative Neoplasms: From Molecular Landscape to Therapeutic Implications.Semantic proximity Read ↗

Molecular pathogenesis of the myeloproliferative neoplasms.Semantic proximity Read ↗

Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.Semantic proximity Read ↗

Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging DataSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.